Sandoz Mulls At-Risk Launch For US Natalizumab

Also Provides Detailed Update On US Adalimumab And Wider Biosimilars Business

 
• By Dave Wallace

As part of a wide-ranging discussion of its biosimilars business as it reported nine-month results, Sandoz has revealed that it is considering launching its Tysabri (natalizumab) biosimilar Tyruko “at risk” in the US, while also providing an update on its progress with adalimumab as well as certain key pipeline assets.

Businessman at chalkboard considers risk - yes or no?
Sandoz is considering whether to launch its Tyruko natalizumab biosimilar ‘at risk’ in the US • Source: Shutterstock

More from Biosimilars

More from Products